Loading…
PTHS
Pelthos Therapeutics Inc.
NYSE American· Healthcare· Biotechnology· CUSIP 171126204
$24.73-1.08%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $94.68M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$28.63
- ROE
- —
- Profit margin
- -199.50%
- Revenue growth
- —
- Beta
- 3.13
- 52-week high
- $37.50
- 52-week low
- $18.19
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -41.1% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $31.00 | $6.41 | |
| P/S | — | 6.2x | — |
| P/B | — | 2.7x | — |
| EPS | -$23.04 | -$14.27 | |
| Profit margin | — | -257.93% | — |
| ROE | — | -111.41% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DHDefinitive Healthcare Corp. | $0.89 | — | 0.7x | — | -78.37% | $95M |
| KLRSKalaris Therapeutics, Inc. | $4.03 | — | 1.7x | — | -79.91% | $95.93M |
| ACHAccendra Health Inc | $1.21 | — | — | — | — | $93.05M |
| CGTXCognition Therapeutics Inc | $1.02 |
About the company
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
- 92
- Durham, United States
Company description provided by Yahoo Finance.